Navigation Links
NOVAVAX Reports Third Quarter 2010 Financial Results
Date:11/5/2010

ROCKVILLE, Md., Nov. 5, 2010 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced financial results for the third quarter ended September 30, 2010.

Novavax reported a net loss of $10.4 million, or $0.10 per share, for the third quarter of 2010 compared to a net loss of $7.5 million, or $0.08 per share, for the third quarter of 2009.  For the nine months ended September 30, 2010, the net loss was $31.2 million, or $0.30 per share, compared to a net loss of $24.4 million, or $0.30 per share, for the same period in 2009.  The primary reason for the increased loss for the third quarter of 2010 as compared to the same period in 2009 was higher research and development spending to support the company's clinical trials related to its H1N1 and seasonal influenza vaccine candidates.  Research and development expenses for the third quarter of 2010 were $7.9 million as compared to $5.3 million in the same period in 2009.  General and administrative expenses were $2.8 million for the third quarter of 2010 as compared to $3.2 million in the same period in 2009.

As of September 30, 2010, the company had $36.9 million in cash, cash equivalents and short-term investments compared to $43.0 million as of December 31, 2009.  

Recent ActivitiesDuring the third quarter, Novavax:

  • completed a 6-month safety evaluation of more than 3,500 subjects enrolled in the second stage of the company's H1N1 clinical trial in Mexico and found no vaccine-related serious adverse events.  The final Clinical Study Report is expected to be completed by the end of 2010 and to support development of our pandemic and seasonal influenza VLP vaccines in other countries, including the United States;
  • submitted final revisions to its proposal to HHS BARDA to provide recombinant influenza vaccines and manufacturing capabilities for pandemic prep
    '/>"/>

  • SOURCE Novavax, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Novavax to Report Third Quarter 2010 Financial Results on November 5, 2010
    2. NOVAVAX to Present at BIO Investor Forum
    3. NOVAVAX to Present at Stifel Nicolaus Conference
    4. NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures
    5. NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines
    6. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2010
    7. Novavaxs Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
    8. NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results
    9. NOVAVAX to Present at 22nd Annual ROTH OC Growth Stock Conference
    10. NOVAVAX to Present at Cowen and Companys 30th Annual Health Care Conference
    11. NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy Adults
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... HILL, N.C. , July 11, 2014 /PRNewswire/ ... analysis approaches are evolving across industry sectors to ... now examining better ways to engage with and ... consumers inform themselves and make critical purchasing decisions. ... benchmarking firm, Best Practices, LLC, one area where ...
    (Date:7/11/2014)... Research and Markets  has announced the ... report to their offering. ... a hollow needle commonly used with a syringe to ... fluids from it. A hypodermic needle is used for ... cannot be ingested. Hypodermic needles are broadly classified into ...
    (Date:7/11/2014)... July 11, 2014 According to ... "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization ... and Forecast, 2013-2019" the global endoscopy devices market was ... expected to grow at a CAGR of 6.8% from ... USD 36.9 billion in 2019. Browse the ...
    Breaking Medicine Technology:New Technologies Transforming Consumer Marketing Research Playbook 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6
    (Date:7/14/2014)... 13, 2014 (HealthDay News) -- Eye tests could be ... Alzheimer,s disease, two new studies suggest. In one ... certain eye test found a significant association between levels ... and levels of the plaques in the brain. Beta-amyloid ... This type of eye test could be used ...
    (Date:7/14/2014)... MONDAY, July 14, 2014 (HealthDay News) -- Being physically ... risk for Alzheimer,s disease and other types of dementia, ... our studies, we found that physical exercise at various ... Dr. Yonas Geda from the Mayo Clinic, said in ... results, but they are not yet conclusive. More research ...
    (Date:7/14/2014)... HealthDay Reporter MONDAY, July 14, 2014 ... multiple health issues, but dementia isn,t one of them, according ... even delay dementia, the researchers found. "For those who ... with a later age of developing full-blown dementia compared to ... Woodruff, an assistant professor of neurology at the ...
    (Date:7/14/2014)... 14, 2014 Follow ... liquid chromatography or UPLC is a new ... chromatography that involves the use of extremely ... separate chromatographic compounds. This highly sensitive qualitative ... and analysis of chromatography samples. UPLC functions ...
    (Date:7/14/2014)... Clara, California (PRWEB) July 14, 2014 ... America for the 6th Annual 5K run and one-mile ... America, winds through the park attractions, and finishes inside ... event has raised over $150,000 for the Mission City ... throughout Santa Clara County. , Seasoned athletes, part-time ...
    Breaking Medicine News(10 mins):Health News:Eye Tests Might Help ID Alzheimer's, Studies Suggest 2Health News:Staying Active May Help Prevent Dementia 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 3Health News:Need for Faster Sample Analysis Drives Demand for UPLC, According to New Trend Report Published by Global Industry Analysts, Inc. 2
    ... liver disease (NAFLD) is the most common cause of ... for patients with NAFLD is currently available//. Understanding the ... patients with NAFLD is important for patient counseling as ... ,To deal with these issues, researchers from Mayo Clinic ...
    ... genetically modified mosquito has been created that wipe out natural ... of the world such as India and South Asia. ... the wild in an attempt to combat malaria that is ... ,A similar attempt was made in India in 1970s ...
    ... to start its Phase III cancer vaccine trial against ... is the new skin cancer vaccine developed by Antigenics.// ... 322 patients failed to meet the required statistically significance ... was not shown to have any better results compared ...
    ... news for adults with acne and resultant facial scarring. ... Surgery, the medical journal of the American Society for ... - or non-ablative - lasers showed significant improvement of ... common with ablative procedures, such as facial resurfacing, dermabrasion ...
    ... survival rate of women with breast cancer has increased by ... years//. The experts feel that the increase in breast cancer ... detection of breast cancer and also due to more effective ... of cancer. ,Professor Michel Coleman, Epidemiologist, Cancer Research ...
    ... found that it is better to insert drug-coated stents ... who have diabetes//. ,The study author Dr. ... University Hospital in Madrid said that the results of ... have poorer prognosis as compared to non-diabetics after angioplasty. ...
    Cached Medicine News:Health News:Weight reduction by 5% may help in treating nonalcoholic fatty liver disease 2Health News:Breast cancer women has shown an increase in survival rates 2
    ... a low osmolar ionic dimer. Each ... meglumine, 196 mg of ioxaglate sodium ... disodium as a stabilizer. The solution ... each milliliter and provides 32% (320 ...
    ... IMAGOPAQUE is a non-ionic monomeric contrast ... in adults and children. After a decade ... 3.5 million examinations, IMAGOPAQUE has proven to ... effort in hundreds of radiology departments.Results from ...
    ... is a liver-specific contrast agent approved for ... Its introduction expands the Amersham Health portfolio ... injected intravenously, TESLASCAN aids in the detection, ... Imaging can begin within minutes of injection, ...
    ... a new Contrast Agent for ... of stabilized SF6 microbubbles. The ... between 1 and 10 m, ... 2 and 5 x 108 ...
    Medicine Products: